ProQR Therapeutics N.V.
corporate_fare Company Profile
ProQR Therapeutics N.V. (NASDAQ:PRQR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for PRQR at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- ProQR Reports Q1 2026 Results, Advances RNA Editing Pipeline, and Refines Lead Program Strategy
- Shareholders to Vote on Major Capital Increase and Share Issuance Authority
- ProQR Nominates Pharma Veteran Dr. Lykke Hinsch Gylvin to Board of Directors
- ProQR Details Expanded RNA Editing Pipeline, New Programs, and Clinical Milestones
- ProQR Unveils Expanded Pipeline, Targets Multiple Clinical Data Readouts Through Mid-2027
Financial Snapshot
Insider Transactions
PRQR files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.